Neurocrine Biosciences   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: San Diego CA United States (1992)

Organization Overview

First Clinical Trial
2001
NCT00014677
First Marketed Drug
2017
valbenazine (ingrezza)
First NDA Approval
2017
valbenazine (ingrezza)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

NEUROCRINE | Neurocrine Biosciences